Table 5 Comparisons of sTIL counts in core needle biopsy and post-NACT surgical specimen according to residual cancer burden (RCB).

From: Evaluation of PD-L1 and tumor infiltrating lymphocytes in paired pretreatment biopsies and post neoadjuvant chemotherapy surgical specimens of breast carcinoma

Comparisons of sTILs count in core needle biopsy and post-NACT

Total N = 122*

Pathological response

OR (95%CI, p)#

RCB-I to III 97 (79.5%)

pCR 25 (20.5%)

Increased

32 (25.2%)

17 (17.5%)

2 (8.0%)

Ref

Stable positive

28 (22.0%)

18 (18.5%)

4 (16.0%)

1.89 (0.31–11.68, p = 0.49)

Stable negative

40 (31.5%)

41 (42.3%)

8 (32.0%)

1.66 (0.32–8.83, p = 0.54)

Decreased

27 (21.3%)

21 (21.7%)

11 (44.0%)

4.45 (0.87–22.88, p = 0.07)

  1. Values in bold indicate data of statistical significance.
  2. *Five women with RCB had no tissue post-NACT for sTILs evaluation; Ref: reference value. pCR: pathological complete response; RCB: residual cancer burden; sTILs: stromal tumor infiltrating lymphocytes; NACT: neoadjuvant chemotherapy. #p value calculation using Pearson’s Chi-squared test.
Back to article page